RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

BACKGROUND: Cutaneous squamous-cell carcinomas and keratoacanthomas are common findings in patients treated with BRAF inhibitors. METHODS: We performed a molecular analysis to identify oncogenic mutations (HRAS, KRAS, NRAS, CDKN2A, and TP53) in the lesions from patients treated with the BRAF inhibit...

সম্পূর্ণ বিবরণ

সংরক্ষণ করুন:
গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক: Su, Fei, Viros, Amaya, Milagre, Carla, Trunzer, Kerstin, Bollag, Gideon, Spleiss, Olivia, Reis-Filho, Jorge S., Kong, Xiangju, Koya, Richard C., Flaherty, Keith T., Chapman, Paul B., Kim, Min Jung, Hayward, Robert, Martin, Matthew, Yang, Hong, Wang, Qiongqing, Hilton, Holly, Hang, Julie S., Noe, Johannes, Lambros, Maryou, Geyer, Felipe, Dhomen, Nathalie, Niculescu-Duvaz, Ion, Zambon, Alfonso, Niculescu-Duvaz, Dan, Preece, Natasha, Robert, Lídia, Otte, Nicholas J., Mok, Stephen, Kee, Damien, Ma, Yan, Zhang, Chao, Habets, Gaston, Burton, Elizabeth A., Wong, Bernice, Nguyen, Hoa, Kockx, Mark, Andries, Luc, Lestini, Brian, Nolop, Keith B., Lee, Richard J., Joe, Andrew K., Troy, James L., Gonzalez, Rene, Hutson, Thomas E., Puzanov, Igor, Chmielowski, Bartosz, Springer, Caroline J., McArthur, Grant A., Sosman, Jeffrey A., Lo, Roger S., Ribas, Antoni, Marais, Richard
বিন্যাস: Artigo
ভাষা:Inglês
প্রকাশিত: 2012
বিষয়গুলি:
Article
অনলাইন ব্যবহার করুন:https://ncbi.nlm.nih.gov/pmc/articles/PMC3724537/
https://ncbi.nlm.nih.gov/pubmed/22256804
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1105358
ট্যাগগুলো: ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!

অনুরূপ উপাদানগুলি